Last updated on April 24, 2014 at 21:24 EDT

Bioniche E. coli O157 Vaccine to be Used in an On-Farm Intervention Study in Sweden

April 18, 2013

-vaccine to be used under import permit on cattle farms to control
serious human illness-

BELLEVILLE, ON, April 18, 2013 /PRNewswire/ – Bioniche Life Sciences Inc. (TSX:
BNC) (ASX: BNC), a research-based, technology-driven Canadian
biopharmaceutical company, today announced that its E. coli O157 cattle vaccine (Econiche®) is being shipped to Sweden for on-farm
studies in some Swedish cattle herds. The Swedish National Veterinary
Institute, Swedish Animal Health Service AB and the Swedish Board of
Agriculture have collaborated with Bioniche to arrange for the vaccine
to be granted Special Treatment Certification for this purpose.

Sweden has been testing and monitoring both cattle farm and
slaughterhouse samples for verotoxigenic E. coli (VTEC) for more than three years. The results of this testing have been
correlated to human illness due to VTEC. While more than one type of
VTEC has been associated with human illness in Sweden, a particular
sub-group of the O157 strain, clade 8, has consistently been associated
with the most severe cases of human illness in that country.

“Studies to date have been focused on implementing additional hygiene
procedures on VTEC O157-positive farms and making modifications to
animal movement on-farm and eventually between farms,” said Dr. Erik
Eriksson of the Swedish National Veterinary Institute. “We expect that
immunization of cattle could be very helpful as an additional
intervention on some farms, and could form part of a future control

“The degree of interdepartmental collaboration in Sweden is very
impressive,” said Mr. Rick Culbert, President, Bioniche One Health. “In
North America, there has been difficulty determining who should pay for
an animal vaccine that provides a human health benefit. In Sweden,
however, all agencies work together and keep it simple, by focusing on
the effect of on-farm VTEC controls as measured by associated human

Sweden has been working with on-farm control measures for VTEC that
causes severe disease, and also has plans for a future control program
with involvement of the veterinary organizations representing the
farmers.  If the initial on-farm evaluation of Econiche® works for
Swedish conditions, the Swedish collaborators expect to eventually
progress to a larger, multi-farm vaccination study in certain areas
where verotoxigenic O157 strains of clade 8 predominate.

About E. coli O157

Ruminants, primarily cattle, are considered to be the primary carriers
of verotoxinogenic E. coli O157 (VTEC O157). This bacterium can cause severe illness and can even
be fatal. Spread of the bacteria to humans can be indirect or through direct contact with infected animals
and their manure (environment). For example when ingested by humans
from unpasteurized milk, contaminated uncooked meat, vegetables, other
food products, water or at visitor open farms or petting zoos etc.
Human exposure and infection with E. coli O157 can result in serious health consequences, including abdominal
pain and severe bloody diarrhea. In severe cases, kidney damage can
occur and progress to serious complications and even death. Lingering,
long-term medical conditions can persist in individuals exposed to the
bacterium. These include post-infectious irritable bowel syndrome
(PI-IBS), reduced kidney function, diabetes, hypertension and reactive
arthritis. E. coli O157 is commonly carried by animals and ruminants but will cause the
animals to show no signs of infection even though there is potential
for spread of E. coli O157 in their feces.

An estimated 100,000 cases of human infection with the E. coli O157 organism are reported each year in North America. Two to seven per
cent of those people develop haemolytic uraemic syndrome (HUS), a
disease characterized by kidney failure. Five percent of HUS patients
die, many of them children and senior citizens, whose kidneys are more
sensitive to damage.

About Bioniche One Health

Bioniche One Health is responsible for researching, developing,
manufacturing and marketing veterinary biopharmaceutical products to
improve public health and the environment. The leading initiative for
this division has been the development and commercialization of a
cattle vaccine to reduce the spread of the E. coli O157 bacterium, which can be deadly to humans. The vaccine – Econiche® - is fully registered in Canada, is approved for importation into
Australia, has received Special Treatment Certificate authorization for
UK veterinary surgeons to use on visitor open farms, and now has been
granted an import permit for use on cattle farms in Sweden.

About Bioniche Life Sciences Inc.

Bioniche Life Sciences Inc. is a research-based, technology-driven
Canadian biopharmaceutical company focused on the discovery,
development, manufacturing, and marketing of proprietary and innovative
products for human and animal health markets worldwide. The
fully-integrated company employs more than 200 skilled personnel and
has three operating divisions: Human Health, Animal Health, and One
Health. The Company’s primary goal is to develop and commercialize
products that advance human or animal health and increase shareholder

For more information, please visit www.Bioniche.com.

Except for historical information, this news release may contain
forward-looking statements that reflect the Company’s current
expectation regarding future events. These forward-looking statements
involve risk and uncertainties, which may cause, but are not limited
to, changing market conditions, the successful and timely completion of
clinical studies, the establishment of corporate alliances, the impact
of competitive products and pricing, new product development,
uncertainties related to the regulatory approval process, and other
risks detailed from time to time in the Company’s ongoing quarterly and
annual reporting.

SOURCE Bioniche Life Sciences Inc.

Source: PR Newswire